Biomerica

BMRAPre-clinical

Irvine, United Statesbiomerica.com

Biomerica is a publicly traded diagnostic company with a mission to improve quality of life through high-performing diagnostic products. It leverages a portfolio of over 100 filed patents and a broad product line across multiple disease areas, including gastrointestinal disorders, diabetes, and endocrinology. The company's strategic vision is to become a leader in diagnostic-guided therapies, particularly for IBS, and it maintains a strong scientific advisory board comprised of leading gastroenterologists. Its business model combines proprietary product development with contract manufacturing services for other pharmaceutical and diagnostic organizations.

Market Cap

$6.6M

Focus

Diagnostics

BMRA · Stock Price

USD 2.1931.97 (-93.59%)

Historical price data

AI Company Overview

Technology Platform

Immunoassay-based diagnostic platform (ELISA and rapid test formats) focused on detecting antibodies and biomarkers for chronic diseases, with a specialized focus on IgG-mediated food intolerance testing for Irritable Bowel Syndrome (IBS).

Funding History

Total raised: $10.5M

PIPE$6.5MUndisclosedNov 15, 2021

PIPE$4MUndisclosedMay 15, 2019

Opportunities

The massive, underserved IBS patient population (40M+ in US) represents a prime growth opportunity for the inFoods® IBS test.

Expansion of insurance coverage and physician adoption could rapidly accelerate revenue.

The diagnostic-guided-therapy platform could also be extended to other inflammatory conditions beyond IBS.

Risk Factors

Key risks include slow commercial adoption of the inFoods® test, challenges securing broad insurance reimbursement, competition from larger IVD companies and direct-to-consumer tests, and ongoing debate about the clinical utility of IgG-based food sensitivity testing.

Competitive Landscape

Biomerica competes with IVD giants (Abbott, Roche) in broad markets and with specialized food sensitivity test providers in its core IBS segment. Its differentiation lies in the specific clinical validation of its inFoods® test for IBS by top-tier institutions, its strong Scientific Advisory Board, and its integrated manufacturing capabilities.